Home » Venture Capital » Plandai to Provide New Formula in Diet Industry Profit Quest

Plandai to Provide New Formula in Diet Industry Profit Quest

BALTIMORE, MD — (Marketwired) — 11/20/13 — Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that while high profile weight loss companies are failing to deliver revenue and profits the door is wide open for a new approach from Plandaí Biotechnology, Inc. (OTCQB: PLPL) with its proprietary Phytofare Catechin Complex.

Weak economies and stagnant wages have decreased demand for specialized supplements or diets that are usually relatively expensive and companies like Jenny Craig are suffering the consequences. While the overall rise in obesity seems somewhat inevitable, the growing market for the healthy consumer also appears to be an opportunity for innovative products and technology. Plandaí is well positioned in this segment and results from its weight loss study should confirm this early sometime in 2014.

One of the many benefits of this product will be to aid in the fight against obesity, as several studies have demonstrated that green tea catechins are effective at inducing weight loss, especially when combined with caffeine. The process by which this happens is called “thermogenesis,” which is the body-s ability to create heat. Stimulating thermogenesis forces the body to burn its energy reserves which, once depleted, burns stored fat.

While green tea catechins and caffeine are not weight loss inducers, their effectiveness thus far has been limited for two related main reasons. First, catechins have poor bioavailability, which means they are not absorbed well in the blood stream. So, in order to get an effective dosage, massive quantities have to be ingested. Which leads to the second problem: heretofore, the amount of catechins and caffeine necessary to achieve meaningful weight loss has induced nausea in test patients. Plandaí overcomes both of these problems.

First, the bioavailability of Plandaí product is far superior to any other product on the market, which should produce better results related to benefits like weight loss. Moreover, the Phytofare Catechin Complex is comprised of more than just the EGCG catechin, which should pack an even greater punch through its absorption and weight loss effect. Second, Plandaí entraps its Phytofare in Pheroid — a long-chain fatty acid that protects the molecules as they pass through the digestive tract. This means that larger dosages of the active ingredients can be ingested without producing nausea. Plandaí plans to test the effects of Phytofare Catechin Complex on 90 subjects, including a placebo group, over the course of three months in a human clinical trial. Plandaí expects that these results will provide a catalyst as it enters the weight loss and diet supplement market with a superior product that will appeal health conscious consumers and impact the top line growth in a beneficial way.

This press release contains excerpts of our most recently published article on Plandaí. Goldman Small Cap Research sponsored articles, reports, and updates on Plandai as well as associated disclaimers and disclosures can be accessed or downloaded in their entirety by visiting .

Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

A Goldman Small Cap Research report, update, newsletter, or article is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit .

(OTCQB: PLPL) Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout Targeted industries for the Company-s products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit

Goldman Small Cap Research
Rob Goldman

Short URL: https://www.88finance.com/?p=318694

Posted by on Nov 20 2013. Filed under Venture Capital. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry

You must be logged in to post a comment Login


© 2019 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia

Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de